American journal of otolaryngology · 2024
Bilateral internal superior laryngeal nerve injections for unexplained chronic cough.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bowen Andrew Jay, Roitman Ariel, Ring Sydney, Francis David O, Davis Ruth J, McCulloch Timothy, Dailey Seth H
Аннотация
OBJECTIVE: Internal Superior laryngeal nerve (iSLN) injections with steroids and anesthetic for Unexplained Chronic Cough (UCC) was initially described as a unilateral injection. This study reports the safety profile and patient-reported outcomes of concurrent bilateral iSLN injections for UCC.
STUDY DESIGN: Retrospective chart review.
SETTING: Tertiary center.
METHODS: A chart review from 2018 to 2023 was performed for patients with UCC who underwent bilateral iSLN injections. Demographics, clinical history, and physical exam findings were recorded, along with any post-injection complications. The primary outcome was patient-reported percent improvement in cough symptoms. Nonparametric statistical analyses were performed to examine whether treatment effectiveness differed based on (a) duration of cough, (b) whether an upper respiratory illness (URI) preceded the start of the cough, (c) had undergone prior speech therapy or (d) neuromodulator treatment for cough, (e) laterality of symptoms, and (f) demonstrated abnormal flexible laryngoscopy/stroboscopy findings.
RESULTS: 12 UCC patients underwent a median of 2 injections (Interquartile Range (IQR): 1-5.5 injections) for a total of 42 injections). There were no aspiration events and only 3 self-limited minor complications. 75 % of patients reported improvement with at least one of their injections with a median percentage response of 73 % (IQR: 26-89 %) and a reported median duration of response of 2.2 months (IQR: 1.2-3.2 months). Nonparametric testing revealed greater responses to injection in patients with abnormal flexible laryngoscopy/stroboscopic findings with their initial injection (p ≤0.02).
CONCLUSION: Bilateral concurrent iSLN injections are a safe and effective way of treating UCC that may require fewer visits to effectively treat UCC.
STUDY DESIGN: Retrospective chart review.
SETTING: Tertiary center.
METHODS: A chart review from 2018 to 2023 was performed for patients with UCC who underwent bilateral iSLN injections. Demographics, clinical history, and physical exam findings were recorded, along with any post-injection complications. The primary outcome was patient-reported percent improvement in cough symptoms. Nonparametric statistical analyses were performed to examine whether treatment effectiveness differed based on (a) duration of cough, (b) whether an upper respiratory illness (URI) preceded the start of the cough, (c) had undergone prior speech therapy or (d) neuromodulator treatment for cough, (e) laterality of symptoms, and (f) demonstrated abnormal flexible laryngoscopy/stroboscopy findings.
RESULTS: 12 UCC patients underwent a median of 2 injections (Interquartile Range (IQR): 1-5.5 injections) for a total of 42 injections). There were no aspiration events and only 3 self-limited minor complications. 75 % of patients reported improvement with at least one of their injections with a median percentage response of 73 % (IQR: 26-89 %) and a reported median duration of response of 2.2 months (IQR: 1.2-3.2 months). Nonparametric testing revealed greater responses to injection in patients with abnormal flexible laryngoscopy/stroboscopic findings with their initial injection (p ≤0.02).
CONCLUSION: Bilateral concurrent iSLN injections are a safe and effective way of treating UCC that may require fewer visits to effectively treat UCC.